98% up Saxagliptin 361442-04-8

Min.Order / FOB Price:Get Latest Price

1 Kilogram	FOB Price:USD 825.0000 -1100.0000

1 Kilogram

FOB Price:USD 825.0000 -1100.0000

Min.Order :1 Kilogram
Purity: 99% up
Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram

Keywords

Saxagliptin 361442-04-8 Saxagliptin 361442-04-8

Quick Details

Appearance:Yellow powder
Application:API
PackAge:1kg/bag ;5kg/drum
ProductionCapacity:10|Metric Ton|Month
Storage:low temperature storage
Transportation:in low tempreture

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Details:

Product name	Saxagliptin
CAS No.	361442-04-8
Molecular Formula	C18H25N3O2
Molecular Weight	315.415
Quality Standard	98% up by HPLC
Appearance	White powder

ITEMS	SPECIFICATION	RESULT
Appearance	White powder	Complies
Odor	Characteristic	Complies
Assay	≥ 98%	99.22%
Sieve analysis	100% pass 80 mesh	Complies
Heavy metals	< 10 ppm	Complies
As	< 0.1ppm	0.05 ppm
Pb	< 0.1ppm	0.05 ppm
Cd	< 0.1ppm	0.05 ppm
Residual solvents	< 100 ppm	Complies
Residual pesticide	Negative	Complies
Total plate count	< 1000 cfu/g	Complies
Yeast & Mold	< 100 cfu/g	Complies
E. Coli	Negative	Complies
Salmonella	Negative	Complies

Conclusion	The sample complies with the above specification

Saxagliptin is a highly potent dipeptidyl peptidase-4 (Dipeptidyl Peptidase 4, DPP-4) inhibitor. By selectively inhibiting DPP-4, it can increase endogenous glucagon-like peptide-1 ( Glucagon-like Peptide-1, GLP-1) and glucose-dependent insulinotropic peptide (Glucose-dependent Insulinotropic Peptide, GIP) levels, thereby regulating blood sugar.

Saxagliptin alone can effectively control blood sugar. Combination therapy with metformin or sulfonylurea can control blood sugar earlier and more effectively, improve the rate of patients' blood sugar compliance, and is safe and well tolerated. The HbA1c-lowering effect of saxagliptin was consistent across age, sex, ethnicity, body mass index (BMI), geographic distribution, and duration of diabetes, and was applicable to most patients with type II diabetes.